Loading...

Neoleukin Therapeutics, Inc.

NLTX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$3.49
$0.05(1.45%)

Neoleukin Therapeutics, Inc. (NLTX) Stock Overview

Explore Neoleukin Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.5/100

Key Financials

Market Cap8.2M
P/E Ratio-0.67
EPS (TTM)$-12.28
ROE-0.49%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

NLTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Neoleukin Therapeutics, Inc. (NLTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.67 and a market capitalization of 8.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NLTXStats details for NLTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NLTXAnalyst Recommendations details for NLTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

CEO

Ms. Donna M. Cochener-Metcalfe J.D.

Employees

7

Headquarters

188 East Blaine Street, Seattle, WA

Founded

2014

Frequently Asked Questions

;